A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD)

Miguel Orri, Lucy Abraham, Annamaria Giraldi

9 Citationer (Scopus)

Abstrakt

Female sexual arousal disorder (FSAD) is a condition that can affect women of all ages and have a significant negative impact on emotional well-being.
OriginalsprogEngelsk
TidsskriftThe journal of sexual medicine
Vol/bind10
Udgave nummer10
Sider (fra-til)2484-96
Antal sider13
ISSN1743-6095
DOI
StatusUdgivet - okt. 2013

Fingeraftryk

Dyk ned i forskningsemnerne om 'A phase 2a multicenter, double-blind, placebo-controlled, crossover trial to investigate the efficacy, safety, and toleration of CP-866,087 (a high-affinity mu-opioid receptor antagonist) in premenopausal women diagnosed with female sexual arousal disorder (FSAD)'. Sammen danner de et unikt fingeraftryk.

Citationsformater